Clinical significance of combined examination of pretreatment serum CYFRA21-1 and SCCAg in cervical cancer patients
- PMID: 19448420
Clinical significance of combined examination of pretreatment serum CYFRA21-1 and SCCAg in cervical cancer patients
Abstract
Background and objective: Cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) can be used for the quantitative examination of fragment of cytokeratin 19, and is a valuable tumor marker in various malignancies. This study was to investigate the significance of pretreatment serum CYFRA21-1 and squamous cell carcinoma antigen (SCCAg) in diagnosis and their correlations to the clinicopathologic features of cervical carcinoma.
Methods: One hundred cervical carcinoma patients underwent pretreatment serum CYFRA21-1 and SCCAg evaluation; 20 healthy women were subjected as control. The specificity and sensitivity of CYFRA21-1 and SCCAg as diagnostic indexes were analyzed; their correlations to clinicopathologic features were investigated through univariate and multivariate analyses.
Results: The specificity of CYFRA21-1 and SCCAg in diagnosing cervical cancer were both 100%. The sensitivity of CYFRA21-1 and SCCAg in diagnosing cervical cancer were 36.0% and 47.0% respectively, without significant difference. The combined examination of CYFRA21-1 and SCCAg elevated the sensitivity to 60.0%, which was significantly higher than that of examining CYFRA21-1 alone. Univariate analysis showed elevation of CYFRA21-1 was related with FIGO stage and tumor size; elevation of SCCAg was related with pathologic type, tumor size, deep stromal invasion and pelvic node metastasis. Multivariate analysis showed that elevation of CYFRA21-1 had no relationship with any factors, while elevation of SCCAg was related with deep stromal invasion and pelvic node metastasis. The sensitivity of SCCAg in predicting pelvic node metastasis and deep stromal invasion were significantly higher than those of CYFRA21-1 (75.0% vs. 29.2%, p = 0.001; 55.8% vs. 26.9%, p = 0.024), and the addition of CYFRA21-1 to SCCAg could not significantly improve the sensitivity compared with SCCAg alone (79.2% vs. 75.0%, p > 0.05; 63.5% vs. 55.8%, p > 0.05).
Conclusion: The value of pretreatment serum CYFRA21-1 as predictor of pelvic node metastasis and deep stromal invasion is less significant compared with that of SCCAg. For cervical squamous cell cancer, SCCAg is the preferred tumor marker.
Similar articles
-
[Correlation of serum squamous cell carcinoma antigen with clinico-pathological features and prognosis of squamous cell carcinoma of uterine cervix].Zhonghua Fu Chan Ke Za Zhi. 2007 Jan;42(1):29-33. Zhonghua Fu Chan Ke Za Zhi. 2007. PMID: 17331418 Chinese.
-
[Impact of squamous cell carcinoma antigen in patients with recurrent squamous cell carcinoma of the uterine cervix].Zhonghua Fu Chan Ke Za Zhi. 2008 Jan;43(1):13-7. Zhonghua Fu Chan Ke Za Zhi. 2008. PMID: 18366925 Chinese.
-
Comparison of pre-treatment CYFRA 21 - 1 and SCC-Antigen assay in primary cervical carcinoma - a preliminary report.J Obstet Gynaecol. 2005 Jul;25(5):486-8. doi: 10.1080/01443610500171144. J Obstet Gynaecol. 2005. PMID: 16183586
-
The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.Crit Rev Oncol Hematol. 2008 Apr;66(1):10-20. doi: 10.1016/j.critrevonc.2007.09.002. Epub 2007 Oct 26. Crit Rev Oncol Hematol. 2008. PMID: 17964182 Review.
-
[Tumor makrers in cervical cancer].Ginekol Pol. 2007 Sep;78(9):715-8. Ginekol Pol. 2007. PMID: 18159826 Review. Polish.
Cited by
-
Clinical Utility of Red Blood Cell Distribution Width for the Diagnosis and Prognosis of Cervical Cancer.Int J Gen Med. 2022 Mar 6;15:2597-2606. doi: 10.2147/IJGM.S354569. eCollection 2022. Int J Gen Med. 2022. PMID: 35282652 Free PMC article.
-
A novel immunoassay for the quantization of CYFRA 21-1 in human serum.J Clin Lab Anal. 2013 Jul;27(4):277-83. doi: 10.1002/jcla.21597. J Clin Lab Anal. 2013. PMID: 23852784 Free PMC article.
-
MicroRNA-466 with tumor markers for cervical cancer screening.Oncotarget. 2017 Aug 7;8(41):70821-70827. doi: 10.18632/oncotarget.19992. eCollection 2017 Sep 19. Oncotarget. 2017. PMID: 29050322 Free PMC article.
-
The value of squamous cell carcinoma antigen (SCCa) to determine the lymph nodal metastasis in cervical cancer: A meta-analysis and literature review.PLoS One. 2017 Dec 11;12(12):e0186165. doi: 10.1371/journal.pone.0186165. eCollection 2017. PLoS One. 2017. PMID: 29227998 Free PMC article. Review.